Drug profile · INN
ebola vaccine (mva-bn-filo [recombinant])
MVABEA
ebola vaccine (mva-bn-filo [recombinant]) (MVABEA) is a envelope glycoprotein vaccine antigen.
EMA: withdrawn Antiinfectives for systemic use (J07) J07BX
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — ebola vaccine (mva-bn-filo [recombinant])
- Class
- Antiinfectives for systemic use (J07)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
ebola vaccine (mva-bn-filo [recombinant]) (MVABEA) is a envelope glycoprotein vaccine antigen.
Key facts
INN ebola vaccine (mva-bn-filo [recombinant])
Brand MVABEA
Mechanism Envelope glycoprotein vaccine antigen
Target Envelope glycoprotein
Therapeutic class Antiinfectives for systemic use (J07)
ATC code J07BX
Mechanism of action
Envelope glycoprotein vaccine antigen
Primary target: Envelope glycoprotein
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | withdrawn | — |
Related & competitor drugs
Frequently asked questions
What is ebola vaccine (mva-bn-filo [recombinant])?
ebola vaccine (mva-bn-filo [recombinant]) (MVABEA) is a envelope glycoprotein vaccine antigen.
What is the brand name for ebola vaccine (mva-bn-filo [recombinant])?
MVABEA is a marketed brand name for ebola vaccine (mva-bn-filo [recombinant]). Check FDA Drugs@FDA for the current US label holder and prescribing information.